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   µl                                       Microliter 
Chol                                  Cholesterol 
SL                                     Soy lecithin 
gms                                   Grams 
HCl                                   Hydrochloric acid 
hrs                                     Hours 
mbar                                   millibar 
ml                                       milliliter 
nm                                      nanometer 
PBS                                   Phosphate buffer saline 
pH                                     Negative logarithmic of hydrogen ion concentration                                        
rpm                                    Revolutions per minute 
v/v                                     Volume/volume 
w/v                                    Weight/volume 
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ABSTRACT: 
 
This thesis delineates the development of giant liposomal formulation and application of drug 
loaded giant liposome encapsulated hydrogel as a theranostics formulation. Liposomes of 
varying composition of cholesterol and soy lecithin were prepared by ether infusion-
homogenization method. Optimization of the composition was done on the basis of number 
of liposome formed at different lipid compostion and stirrer speed. Comparative analysis 
showed that among three different compositions (Chol: Soy lecithin; 1:8, 1:12, 1:16w/w) and 
three different stirrer speed (2000g, 4000g, 6000g), giant liposomes prepared from Chol: Soy 
lecithin 1:12 and at stirrer speed of 2000rpm could be considered as suitable candidates for 
the aforementioned application. 
Physico-chemical characterization of the giant liposome was done by morphology 
(microscopy) study, vesicle size distribution profile, stability studies at different pH and 
temperature, efficiency of drug loading, in vitro toxicity of the drug loaded liposomes and 
hemocompatibility. Microscopy study confirmed giant liposomal morphology and this was 
further validated by vesicle size distribution profile using Image J and NI Lab View software. 
Stability studies at different pH and temperature revealed that giant liposomes are stable at 
room temperature and 4
0
C temperature in PBS. In vitro toxicity of the drug loaded liposomes 
were done by using MTT assay method. Hemocompatibility of the liposome formulation was 
checked using goat blood and found to be hemocompatible which ensures (partially) its 
suitability for in vivo systemic application. 
Loading of giant liposomes inside the hydrogel was done using the sodium alginate and 
calcium carbonate solution and 0.1 NHCl. Entrapment of giant liposome inside the hydrogel 
was confirmed by using fluorescence microscope. Then analysis of the mechanical properties 
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was performed using a P3 probe at a test speed of 1mm/sec. From the analysis it was 
observed there is an increase in gel strength with the incorporation of liposome.  
In conclusion, giant liposome loaded hydrogel may be used as advanced pharmaceutical 
formulation for theranostic application. 
Key words: Giant liposome, liposome encapsulated hydrogel, drug loaded liposome. 
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INTRODUCTION: 
Liposomes are the drug delivery systems used for the systemic administration of drugs. 
Liposome, a tiny vesicle made up of the same material as a cell membrane. Its membranes are 
composed of natural phospholipids having a head group attracted to water and a tail group 
which is made up of a long hydrocarbon chain. The tail group is repelled by water and also 
may contain mixed lipid chains containing surfactant properties. In the presence of aqueous 
medium, the heads are attracted to water and line up to form a surface facing the water and 
tails are repelled by water, and line up to form a surface away from the water same as in a 
cell. The hydrocarbon tails of one layer face the hydrocarbon tails of the other layer and the 
combined structure forms a bilayer. When phospholipid membranes are disrupted, they will 
reassemble themselves into tiny spheres which are smaller than a normal cell either as 
bilayers or monolayers. The bilayer structures are known as liposomes and the monolayer 
structures are known as micelles.  As a drug delivery systems liposome played an important 
role in potent drug formulation to improve therapeutics. As a drug delivery system liposomes 
have many advantages such as they provide controlled drug delivery and controlled hydration 
and also provide sustained release and can carry both water and lipid soluble drugs. 
Liposomes are biodegradable, biocompatible, flexible and non ionic. It provides direct 
interaction of the drug with cell and can modulate the distribution of drug and also increase 
the therapeutic index of drugs. Liposomes also have some disadvantages such as less 
stability, low solubility, short half life, high production cost, and quick uptake by cells of 
reticulo endothelial system.  We can construct liposomes containing low or high pH so that 
dissolved aqueous drugs will be charged in the solution. The pH neutralizes within the 
liposome so that protons can pass through some membranes. Then the drug will also be 
neutralized by allowing it to freely pass through a membrane. Liposomes prefer to deliver 
drug by diffusion than by direct cell fusion. Liposome drug delivery is also used to target 
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endocytosis events. Liposomes of a particular size range can make them viable to target 
natural macrophage phagocytosis. Such that in the macrophage’s phagosome, liposomes will 
be digested by releasing its drugs. Liposomes can also used as carriers to deliver dyes to 
textiles, enzymes and nutritional supplements to foods and cosmetics to the skin, pesticides to 
plants. 
  Based upon structural parameters there are different types of liposomes such as medium 
sized unilamellar vesicles, large unilamellar vesicles (>100nm), giant unilamellar vesicles 
(>1µm), multivesicular vesicles (>1µm), multilamellar large vesicles (>0.5µm), oligolamellar 
vesicles (0.1-1µm), small unilamellar vesicles (20-100nm).  Giant liposomes or giant 
unilamellar vesicles (GUV) of lipid memebranes with diameters greater than 1µm have been 
used to investigate the physical properties of membranes such as elasticity, shape change and 
phase separation. Giant liposomes with dimensions of living cells are useful models to: (1) 
study membrane curvature and elasticity under varying conditions; (2) examine interactions 
between lipid membranes and surfaces; (3) record the activity from reconstituted ion 
channels; (4) form planar lipid bilayers over micro fabricated pores; (5) create nano-fluidic 
networks; and (6) make micro scale bioreactors. Liposomes are often used in biological 
research not only because their properties are similar to those of real cell membranes, but also 
because they are large enough to observe and manipulate directly using optical microscope. 
For example, morphological transformation, microdomain information, biopolymer 
encapsulation, enzyme reactivity and association with reagents such as proteins, peptides, 
nucleic acids, etc. have all been investigated using giant liposomes from biophysical and 
biochemical perspectives.  
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REVIEW OF LITERATURE: 
LIPOSOMES: 
A liposome is a tiny bubble (vesicle), made out of the same material as a cell membrane. 
Liposomes can be filled with drugs, and used to deliver drugs for cancer and other diseases. 
Membranes are usually made of phospholipids, which are molecules that have a head group 
and a tail group. The head is attracted to water, and the tail, which is made of a long 
hydrocarbon chain, is repelled by water. In nature, phospholipids are found in stable 
membranes composed of two layers (a bilayer). In the presence of water, the heads are 
attracted to water and line up to form a surface facing the water. The tails are repelled by 
water, and line up to form a surface away from the water. In a cell, one layer of heads faces 
outside of the cell, attracted to the water in the environment. Another layer of heads faces 
inside the cell, attracted by the water inside the cell. The hydrocarbon tails of one layer face 
the hydrocarbon tails of the other layer, and the combined structure forms a bilayer. When 
membrane phospholipids are disrupted, they can reassemble themselves into tiny spheres, 
smaller than a normal cell, either as bilayers or monolayers. The bilayer structures are 
liposomes. The monolayer structures are called micelles. Liposomes are composite structures 
made of phospholipids and may contain small amounts of other molecules [1, 2]. In general, 
liposomes are defined as spherical vesicles with particle sizes ranging from 30nm to several 
micrometers. They consist of one or more lipid bilayers surrounding aqueous compartments, 
where the polar head groups are oriented towards the interior and exterior aqueous phases. 
However, self-aggregation of polar lipids is not restricted to conventional bilayer structures 
which depend on temperature, molecular shape, and environmental and preparation 
conditions but may self-assemble into various kinds of colloidal particles [1, 2]. Liposomes 
are composed of phosphatidylcholine and cholesterol mixed with either phosphatidylserine (-
ve charge) or stearylamine (+ve charge) [3]. Lecithin provides liposomes with aneutral 
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surface and streaylamine and phosphatidic acid components provide positive and negative 
surface charge respectively [4]. Cholesterol is used for formulations in order to reduce quick 
drug leakage [6]. Liposomes can encapsulated and effectively deliver both hydrophilic and 
lipophilic substances and may used as a nontoxic vehicle for insoluble drugs. It is 
biodegradable and hydrophilic, hydrophobic drugs and lipid insoluble drugs or DNA can 
encapsulated in the aqueous core within the liposome to improve their stability or 
bioavailability compared to free drugs or DNA  [4, 5].  One of the characteristic features of 
liposomes is their ability to encapsulate solutions and release them to the external 
environment in response to temperature. Below the phase transition temperature of the 
phospholipid, the bilayer is solid-like and has a low permeability for the diffusion of polar 
molecules. Once heated above its phase transition temperature, the bilayer changes to fluid-
like and its permeability can substantially increase. This property can be used for controlled 
release (or uptake) from liposomes in applications such as medicine or cosmetics [12]. 
Liposomes can be classified by either their structural properties or the basis of their 
preparation. The main types are listed and their characteristics are outlined in the table below. 
Vesicle Types Abbrev Diameter Size Number of lipid bilayers 
 
Small unilamellar vesicles SUV Diameter of 20-100nm. One lipid bilayer 
Large unilamellar vesicles LUV Diameter of 100nm. One lipid bilayer 
Giant unilamellar vesicles GUV Diameter of  1m. One lipid bilayer 
Multilamellar vesicles MLV Diameter of 0.5m. Five to twenty lipid bilayers 
Oligolamellar vesicles OLV Diameter of 0.1-1m. Approximately five lipid bilayers 
Multivesicular vesicles MMV Diameter of  1m. Multicompartmental  structure  
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LIPOSOME IN THERAPEUTICS: 
The pharmacokinetics and biodistribution of liposome encapsulated drugs are controlled by 
the interplay of two variables: the rate of plasma clearance of the liposome carrier and the 
stability of the liposome-drug association in circulation [10]. The rate of leakage or efflux of 
drug from liposomes should be slower than the rate of liposome clearance from blood [10]. In 
general successful formulation of stable liposomal drug product requires the following 
precautions like 1) processing with fresh, purified lipids and solvents 2) avoidance of high 
temperature and excessive shear forces, 3) Maintenance of low oxygen potential (Nitrogen 
purging), 4) Use of antioxidant or metal chelators, 5)Formulating at neutral pH and 6)Use of 
lyo-protectant when freeze drying [8]. Capacity to entrap ions and small and large molecules 
along with their low permeability presented considerable advantages as a drug delivery 
system.  Their ability to potentiate the pharmacological efficacy of various drugs in vitro 
against mammalian cultured cells enhanced their prospects as a drug delivery system [9]. 
Liposomes can be loaded with magnetic nanoparticles for magnetic targeting and/or with 
colloidal gold, silver nanoparticles or fluorescent molecules for diagnostic and microscopic 
analysis and thermosensitive magnetoliposomes may increase the concentration of the 
encapsulated drugs in targeted tumor site by applying an external magnetic field [11].  
Table: 2 Summary of the reports on therapeutic application of liposome 
Sl.No Therapeutic activity Liposome used Ref 
1 Anti cancer vaccine against lung 
cancer 
DOTAP cholesterol 
cationic liposome 
Junfeng Zhang 
et al., 2013 
2 Drug delivery in cancer therapy Long-circulating 
liposomes 
Alberto Gabizon 
et al., 1997 
3 Antitumor vaccine against pancreatic 
cancer  
PEGylated liposome Cha-Eun Kim et 
al., 2012 
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4 Ultrasound-triggered therapeutic 
drug delivery 
 
Paclitaxel-liposome–
microbubble complex 
 
Fei Yan et al., 
2013 
5 Gene delivery and vaccine therapy Cationic liposome Tiago Albertini 
Balbino et al., 
2013 
6 Liposome-based antigen delivery for 
cancer immunotherapy 
pH sensitive fusogenic 
liposome 
Eiji Yuba et al., 
2013 
7 
Sonodynamic therapy (SDT):  A 
novel treatment of cancer  
Sonosensitizer liposome 
 
Zhi-Jun Dai et 
al., 2013 
8 Label free DNA sensing  Gold surface supported 
spherical liposome 
M. Bhuvana et 
al., 2013 
9 Inhibition of metastatic lung cancer Liposome encapsulated 
all trans retinoic acid 
(ATRA)  
Siddikuzzaman 
et al., 2012 
10 Tumor growth suppression by 
gadolinium-neutron capture therapy 
 
Gadolinium-entrapped 
liposome  
 
Novriana Dewi 
et al., 2012 
11 Pulmolonary delivery for local lung 
disorders 
liposome Michael I. 
Ugwoke et al. 
12 Potential Diagnostic and Therapeutic 
Agent for Human Head-and-Neck 
Cancer Cells 
Liposome-based 
Nanoprobe with 
Antibody 
Y. Kuo et al., 
2012 
13 For improving brain delivery and 
therapeutic efficacy on brain glioma 
in animals 
Liposome formulated 
with TAT-modified 
cholesterol 
Yao Qin et al., 
2011 
14 Pancreatic cancer treatment Cationic liposome Feng Yang et 
al., 2011 
15 Light and electron microscopy 
characterization of intra-articular 
drug delivery 
Collagen–liposome 
entrapped chondroitin 
sulfate  
Otilia Zarnescu 
et al., 2011 
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16 MRI monitoring of intratumoral drug 
delivery 
Thermosensitive 
liposome 
Tatsuaki Tagami 
et al., 2011 
17 Metastatic breast cancer Pegylated liposomal 
doxorubicin 
Shailendra 
Verma et al., 
2008 
18 Ocular drug delivery 
 
Liposome coated with 
low molecular weight 
chitosan 
Ning Li et al., 
2009 
19 Novel drug delivery system aiming 
for radio-chemo-concurrent cancer 
therapy 
Thermal neutron-
sensitive liposome 
 
Ken Akamatsu, 
2009 
20 Enhanced therapeutic effects in 
cerebral ischemia 
 
Liposome-encapsulated 
citicoline  
 
Pedro Ramos-
Cabrer et al., 
2011 
21 Vaginal vaccine delivery against 
HIV-1 
Liposome-based freeze-
dried rods 
Prem N. Gupta 
et al., 2010 
22 High therapeutic efficacy for colon 
tumors 
Irinotecan-loaded 
liposome 
Yoshiyuki 
Hattori et al., 
2009 
23 Preventive against ischemia-
reperfusion injury in a rat middle 
cerebral artery occlusion 
Liposome-encapsulated 
luteolin  
Gang Zhao et 
al., 2011 
24 Treatment of Hepatocellular 
Carcinoma and Hepatic Metastases 
 
Thermosensitive 
Liposomes 
 
Mark W. 
Dewhirst et al., 
2013 
25 Intratumoral drug delivery and 
efficacy 
 
Stealth thermosensitive 
liposomes 
 
Li Li et al., 2013 
26 Vaccine against tuberculosis of 
pseudo-ternary complexes 
Peptide-DNA-cationic 
liposome 
 
Rogério Silva 
Rosada et al., 
2012 
27 Immunological adjuvant efficacy 
against Newcastle disease vaccine 
Glycyrrhetinic acid 
liposome  
Xiaojuan Zhao 
et al., 2011 
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28 DNA vaccination efficiently evokes 
anti-HPV E6 and E7 CTL responses 
 
Oligomannose liposome-
DNA complex 
 
Masahito 
Mizuuchi et al., 
2012 
29 Enhances Radiotherapy and 
Chemotherapy to Suppress Tumour 
Growth and Metastasis in Mice 
 
Liposome-Encapsulated 
Hemoglobin 
 
C. Murayama et 
al., 2011 
30 Endocytosis and intracellular 
trafficking of for gene delivery 
 
Cholesterol based 
cationic liposome 
K. Doh,  et al., 
2007 
 
 
 
 
GIANT LIPOSOMES: 
Giant liposomes are large (>1µm diameter), spherical vesicles consisting of one or more 
phospholipid bilayers surrounding an aqueous center. They have been used for physical and 
biological investigations such as shape change of liposomes, elastic properties of lipid 
membranes, interaction of cytoskeleton proteins with membranes and dynamic structures of 
biomembranes [7]. Giant liposomes with dimensions of living cells are useful models to 
study membrane curvature and elasticity under varying conditions, to examine interactions 
between lipid membranes and surfaces, to record the activity from reconstituted ion channels, 
to form planar lipid bilayers over microfabricated pores, to create nanofluidic networks and to 
make microscale bioreactors [6].  
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LIPOSOME ENCAPSULATED HYDROGEL: 
Hydrogel is a network of polymer chains that are hydrophilic. Hydrogels are highly absorbent 
natural or synthetic polymer and also possess a degree of flexibility very similar to natural 
tissue due to their significant water content. Hydrogel have the ability to absorb large amount 
of water. Alginate is a biocompatible and biodegradable polysaccharide obtained from sea 
algae, consisting of mannuronate and guluronate homopolymer blocks. While sodium 
alginate is water soluble, it rapidly forms a gel with multi-valent cations such as Ca2+. This 
property is used for the microencapsulation of various compounds including enzymes and 
whole cells. Alginate is also used as a wound dressing with haemostatic properties [12]. The 
main advantage of embedding liposomes into the alginate carrier compared to free individual 
liposomes is the protection of liposomes from external factors that could lead to their 
destabilisation and the possibility to keep a statistically significant number of liposomes in a 
single location rather than dispersing them throughout the host environment. Embedding of 
liposomes into alginate particles makes it possible to build more complex structures in the 
future that may contain other components such as immobilized enzymes or catalysts for 
facilitating chemical reactions [12]. Liposomal hydrogel as a wound dressing provides a 
barrier that effectively prevents the contamination of the wound and further progression of 
infection to deeper tissues. The drug encapsulated within the liposomes increases the drug 
concentration locally and decreases systemic drug concentration and hydrogels combine the 
features of moist wound healing with good fluid absorbance. And act as a barrier against 
bacteria, oxygen permeability, it is easy to handle, hence it is useful as a moist wound 
dressing material. Besides hydrogels by nature of transparency promote monitoring of wound 
healing [13]. It allows a prolonged release of drugs at the specific site, by efficient  
intracellular delivery of drug loaded liposomes. It is efficient also for the delivery and 
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modified release of protein drugs. It is of simple topic application on epithelial ulcers and it 
can be used on human beings, and mammalians, to treat dermatological diseases [14]. It also 
used as coating for biosensors, contrast agents for imaging, and scaffolds for tissue 
engineering [15]. Injectable hydrogels as one hydrogel type have been extensively employed 
as cell carriers for in vivo tissue engineering. The advantages of using injectable hydrogels lie 
in that they have high moldability, capable of filling irregular shaped defects; can be 
delivered to the in vivo environment by limited surgical invasion such as minimally invasive 
surgery; and are readily for cell and drug encapsulation. After being delivered in vivo, the 
injectable hydrogels solidify to form tissue constructs, which are exposed to the in vivo 
environment and therefore are capable of experiencing local biological and mechanical cues 
that may enhance tissue development [16]. 
 
MATERIALS AND METHODS:  
Materials:  Lecithin (HIMEDIA), Cholesterol (HIMEDIA), Diethyl ether (MERCK), 5- 
Bromo Uracil, 0.1NNaOH, 0.1NHCl, Coomassie brilliant blue G, Floral yellow (fluorescent 
dye) and all other chemicals needed were purchased from HIMEDIA. Every preparation was 
carried out with double distilled water. 
Methods: 
Preparation of giant liposomes and drug loaded giant liposopme:  
Giant liposomes were prepared by modified ether infusion method namely ether infusion-
homogenization method. Cholesterol and soya lecithin were taken at a ratio of 1:12 in a 
falcon tube and dissolved in diethyl ether of almost 3ml. 100ml of PBS buffer was taken in a 
500 ml beaker and warmed upto 55
0
C using water bath. During the process of 
homogenization the temperature of PBS should not decrease below 55
0 
C. It should be 
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maintained at 55
0
 C. So to maintain this temperature of PBS, the heated PBS was transferred 
to a plastic measuring cylinder and the cylinder was kept inside water bath. The temperature 
of the water bath maintained at 65
0
C. After that the prepared solution was infused 
periodically through pipette into the preheated (at 55
0 
C) PBS (pH 7.4) under continuous 
homogenization (to produce continuous stirring effect) for 25 min. At that temperature 
diethyl ether got evaporated leaving liposomes of various sizes. RPM was maintained at 
2000. Similarly,  for the preparation of drug loaded giant liposomes, 1 gm of 5-flurouracil 
was taken in a 100 ml PBS and mixed it by putting in stirrer for 15 to 20 minutes. Then 
liposome suspension was prepared. 
 
Physical Characterization of Giant liposomes: 
- Morphology Studies (Microscopy studies): 
Giant liposomes were viewed using Leica DM750 microscope and were counted 
manually. 
- Vesicle size distribution profile: 
Vesicle size distribution profile was analysed by using NI labview software . 
 
Process optimization: 
 (i) Giant liposomes at different RPM: 
Giant liposome solutions were prepared at different RPM (2000g, 4000g, and 6000g) of 
definite lipid composition. Then the study was conducted by microscopy based manual 
counting of liposomes and subsequent NI Lab View based analysis.  
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(ii) Giant liposomes of different lipid ratio:  
Giant liposome solutions of three different lipid ratios (1:8, 1:12 and 1:16) were prepared. 
Then the study was conducted by microscopy based manual counting of liposomes and 
subsequent NI Lab View based analysis.  
Stability study: 
(i) Stability of giant liposomes at different pH: 
Giant liposome was prepared. Then the sample is divided into four groups. Control taken as 
uncentrifuged and to the remaining three samples, PBS buffer, 0.1NHCl, 0.1NNaOH was 
added. Then the study was conducted by microscopy based manual counting of liposomes 
and subsequent NI Lab View based analysis. 
(ii) Stability of giant liposomes at different temperatures through microscopic analysis:  
        Aqueous stability depends on the lipid oxidation due to exposure of time so the stability 
studies are taken different intervals of time in 24hrs, 48 hrs and 72 hrs with respect to 
temperature. Readings are taken from samples at room temperature, 4
0 
C and -20
0
C. Then the 
study was conducted by microscopy based manual counting of liposomes and subsequent NI 
Lab View based analysis. The readings show that giant liposomal solutions are stable at 4
0
C 
rather than room temperature and in -20
0 
liposomes are least stable due to ice crystal 
formation which further leads to rupture of membrane.      
Hemocompatibility tests: 
 Giant liposomes were prepared by ether infusion-homogenization method. 8ml of goat blood 
was taken and 10ml of 0.9% saline was added to that. Positive and negative controls were 
made by adding 0.5ml of 0.01N Hcl and 0.5ml of PBS respectively. Sample was 0.5ml of 
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giant liposomal solution added to 9ml of saline +0.5ml of diluted blood. The samples were 
then incubated along with positive and negative controls for 60 min. Then the samples were 
centrifuged along with positive and negative controls at 4000rpm for 10minutes to settle all 
the blood components. If there are any ruptured RBCs then its contents will be released into 
supernatant. Then O.D of supernatant was taken at 545nm. Percentage of haemolysis was 
calculated by using the formula. 
% Hemolysis = 100*(O.D. of sample - O.D. of positive control) / (O.D. of negative control- 
O.D. of positive control) 
Protein loading Studies and Dye entrapment studies: 
The model protein used was BSA. 25 gm of BSA were taken in 100ml PBS. Giant liposomes 
were prepared using the protein solution. Loading was estimated by taking O.D at 595 nm 
using spectrophotometer. BSA standard curve can be taken as reference. Dye used was 
coomassie brilliant blue. 5 mg of coomassie brilliant blue dye were taken in 100ml of PBS 
and warmed up to 55
0
C in a water bath. Then dye loaded liposomal suspension was prepared. 
Then the dye loaded liposomal suspension was centrifuged 2 times at 4000 rpm for 10 
minutes and resuspended in fresh PBS. Then the study was conducted by Leica microscope. 
Fluorescent Microscopy: 
By adding 10mg of floral yellow in 1ml of diethyl ether 0.1% dye solution was prepared. 
From that 500µl was taken and mixed it with lipid solution for the preparation giant 
liposomes. After that samples were centrifuged 2 to 3 times for 10 minutes at 4000rpm for 
washing purpose. Then the pellet obtained was resuspended in 2ml of fresh PBS. Then the 
sample was taken in a eppendruf and carefully wrapped with a brown paper or aluminium foil 
in order to avoid bleaching and characterized using fluorescent microscope. 
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Study of in vitro toxicity of 5-fluorouracil loaded giant liposomes: 
 For the preparation of drug loaded giant liposomes, 1 gm of 5 flurouracil was taken in a 100 
ml PBS and mixed it by putting in stirrer for 15 to 20 minutes. Then liposome suspension 
was prepared. It was then centrifuged and resuspended in 5ml PBS and incubated for 24hr at 
37°C. The releseate containing the drug was filtered through a 0.22µm filter. HeLa cells were 
cultured in MEM /10% FBS and seeded in a 96 well plate at a concentration of 1x10
5
 
cells/ml.  The 10 µl of releasate was administered per well. The toxicity of the cells was 
studied for 24hr by using MTT assay method.  
Preparation of giant liposome encapsulated Hydrogel: 
By adding 1gm of sodium alginate in 100 ml of distilled water (1% w/v) alginate solution 
was prepared. From that 20 ml of alginate solution was taken in a beaker and stirred in a 
magnetic stirrer. During the time of stirring, 0.024 gm of calcium carbonate was added in the 
alginate solution. Then after 5 minutes of proper mixing 1ml of floral yellow dye loaded 
liposomal solution was added slowly. At last 1700µl of 0.1N HCl was added to that solution. 
Then fluorescence microscopy and mechanical testing of the liposome loaded hydrogel was 
done. 
Characterization of giant liposome loaded hydrogel: 
Microscopic characterization: 
The morphology and distribution of the giant liposomes loaded hydrogel was studied using 
fluorescent microscope (Olympus IX71). 
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Analysis of Mechanical Property: 
Gel strength, of the gels was studied using a texture analyzer (Stable Microsystems, TA-HD 
plus, U.K.). The test was performed using a P3 probe at a test speed of 1mm/sec. 
RESULT AND DISCUSSION: 
Liposomes are formed in different morphologies namely small unilamellar vesicles (SUVs), 
large unilamellar vesicles (LUVs), multivesicular liposomes each differing in size, their 
internal volume and some form very large in size generally in micrometers known as giant 
unilamellar vesicles (GUVs). The type of liposome formed depends on method followed. For 
example, sonication usually results in SUVs while ether infusion and ether injection methods 
result in GUVs. Multilamellar vesicles can be later converted to unilamellar and liposomes of 
uniform size can be obtained by extrusion through filter membrane of particular pore size. 
  
Cholesterol is commonly used as lipid for the preparation of liposomes which has highest                                          
melting point (42
o
C) among all lipids present in the cell membrane and hence its function is    
to maintain the integrity of the cell membrane. Usually its concentration is taken in lesser 
compared to other lipids for the preparation of liposomes may be as to vary the membrane 
permeability. 
Figure 1 showed the experimental set up of ether-infusion homogenization method of giant 
liposome synthesis. Figure 2 showed the microscopic view of giant liposomes. Figure 3 
showed the microscopic view of 5-flurouracil drug loaded giant liposomes. 
 
Fig 1: Experimental Setup for the preparation of giant liposomes. 
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Fig 2: Microscopic view of giant liposome at 40X scale 
 
Fig 3: Microscopic view of 5-flurouracil drug loaded giant liposomes 
 
 
Fig 4: Size distribution profile of giant liposomes and drug loaded liposomes (r is in 
micrometer)  
 
 
OPTIMIZATION OF LIPID COMPOSITION AND STIRRER SPEED: 
Giant liposomes of different lipid ratio:  
Giant liposome solutions of three different lipid ratios (1:8, 1:12 and 1:16) were prepared. 
Then the study was conducted by microscopy based manual counting of liposomes and 
subsequent NI Lab View based analysis. When we compared the result of three different lipid 
ratios, we found more number of giant liposomes in the lipid ratio of 1:12 compared to 
another two. 
Giant liposomes at different RPM: 
Giant liposome solutions were prepared at different RPM (2000g, 4000g, and 6000g) of 
definite lipid composition. Then the study was conducted by microscopy based manual 
counting of liposomes and subsequent NI Lab View based analysis.  
 
Fig 5: Microscopic views of liposomes formed at different RPM respectively (2000, 4000 
and 6000 rpm) 
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When we compared the giant liposomes obtained at different RPM, we found that at 2000rpm 
more numbers giant liposomes were formed compared to 4000rpm and 6000rpm due to high 
stirrer speed. 
 
From this table we obtained that for the preparation giant liposomes best combination is the 
1:12 lipid ratio and 2000 rpm stirrer speed. 
STABILITY STUDIES: 
Stability of giant liposomes at different pH: 
Giant liposome samples were divided into four sets. Uncentrifuged samples were taken as 
control and remaining three sets were resuspended in 5ml PBS buffer, 0.1NHCl, 0.1NNaOH . 
Then the study was conducted by microscopy based manual counting of liposomes and 
subsequent NI Lab View based analysis.  
 
Fig 5: Stability studies of giant liposomes at different pH: sample with PBS, sample with 
0.1N NaOH and sample with 0.1N HCl respectively 
 
Fig 6: Size distribution graph of stability studies of giant liposomes at different pH. (r is 
in micrometer)  
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From this study we are concluded that liposomes are stable in PBS and clusters of liposomes 
were obtained in presence of 0.1N HCl. 
Stability of giant liposomes at different temperatures through microscopic analysis:  
 Aqueous stability of liposomes depends on the lipid oxidation. It is observed that lipid 
oxidation kinetics temperature sensitive. Furthermore temperature is often considered as a 
critical parameter for storage. To evaluate the stability of liposome prepared due stability 
studies are taken different intervals (24hrs, 48 hrs and 72 hrs) at three different temperature  
Readings are taken from samples at room temperature, 4
0 
C and -20
0
C. Then the study was 
conducted by microscopy based manual counting of liposomes and subsequent NI Lab View 
based analysis. 
 
 
Fig 7: Temperature stability studies of liposomes at 0hr 
 
Fig 8: Temperature stability studies of liposomes (i) of room temperature at 24 hrs, (ii) 
of 4
0
C at 24 hrs, (iii) of -20
0
C at 24 hrs, (iv) of room temperature at 48 hrs, (v) of 4
0
C at 
48 hrs, (vi) of -20
0
C at 48 hrs, (vii) of room temperature at 72 hrs, (viii) 4
0
C at 72 hrs, 
(ix) of -20
0
C at 72 hrs 
 
The readings show that giant liposomal solutions are stable at 4
0
C rather than room 
temperature and in -20
0 
liposomes are least stable due to ice crystal formation which further 
leads to rupture of membrane.  
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Fig 9: Reduction in liposome number 
 
Fig 10: Size distribution graph of stability studies of giant liposomes at different 
temperature 
It is observed in the size distribution curve there is a certain increase in the size of that 
liposome with incubation. This may happen due to the fusion of giant liposomes. 
Hemocompatibility study: 
Intravenously injected therapeutic agent or carrier system must remain and circulate in the 
blood before reaching the target site. So hemocompatibility of the liposome   system is also 
important as tissue compatibility.  Hemocompatibilty study was conducted using goat blood 
by taking 0.1N HCL as positive control which degrades blood components completely. In 
positive the cell debris control was whitish in colour after centrifugation and supernatant was 
red indicating complete hemolysis of RBCs. 
Percentage hemolysis calculated using,  
100*(O.D. of sample - O.D. of positive control) / (O.D. of negative control- O.D. of positive 
control) 
Percentage of hemolysis by giant liposomes was found to be 5%. 
 
Fig 11: Hemolysis study: Graph showing hemolysis (OD at 545nm) by positive and giant 
liposomes. 
From the result we conclude that giant liposome can be used for systemic application. 
Liposome bilayer is composed of lipids should be compatible to blood components. 
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Protein loading Studies and Dye entrapment studies: 
The model protein used was BSA and the dye used was coomassie brilliant blue. Giant 
liposomes were prepared using the protein solution and loading was estimated by taking O.D 
at 595 nm using spectrophotometer. BSA standard curve can be taken as reference. Dye 
loaded liposomal suspension was prepared and then the dye loaded liposomal suspension was 
centrifuged 2 times at 4000 rpm for 10 minutes and resuspended in fresh PBS. Then the study 
was conducted by Leica microscope. 
 
Fig 12: Microscopic view of dye loaded giant liposomes 
The percentage of protein loading and the percentage dye loading was calculated to be 3%. 
Fluorescence microscopy of giant liposomes: 
 
Fig 13: Fluorescence microscopy of giant liposome 
Drug loading study: 
1 gm of 5 flurouracil was taken in a 100 ml PBS and mixed it by putting in stirrer for 15 to 20 
minutes. Then liposome suspension was prepared. It was then centrifuged and resuspended in 
5ml PBS and incubated for 24hr at 37°C.  
 
Fig 14: Microscopic view of drug loaded giant liposomes 
Considering the protein loading study and dye entrapment study it was concluded that the 
percentage of encapsulation of drug was approximately 3%.  
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Study of cytotoxicity of drug loaded liposomes: 
To study the cytotoxicity of drug loaded liposomes, the liposomes were added to the cell 
culture medium and incubated at 37
0
C 5% CO2 for 24 hours. Control was cells cultured 
without addition of drug loaded liposomes. After 24 hours, MTT assay was done to measure 
the cell proliferation. From the result, drug loaded liposomes showed cytotoxicity index of 
0.26 as control was taken as 1. 
 
Fig 15: Cytotoxic analysis of drug loaded giant liposomes 
Microscopic analysis: Fluorescent images of gel showed that liposomes are evenly 
distributed inside the alginate gel.  It is further evident from the picture that there was no 
agglomeration of liposomes inside the gel.   Liposomes were not degraded inside the gel.    
 
Fig 16: Fluorescence microscopy of giant liposomes loaded hydrogel 
 
 
Analysis Mechanical Property:  
Gel strength study gave indication about the gel strength and brittleness of the gels. These are 
important parameters for the development of products for topical applications. Gel strength is 
defined as the maximum positive force required compromising the gel integrity while the 
brittleness may be defined as the distance penetrated by the probe at the gel rupture. From the 
analysis it is observed there is an increase in gel strength with the incorporation of liposome. 
This is may be because of filler effect of liposomes.  
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Fig 17: Texture analysis graph of liposome loaded hydrogel  
SUMMARY AND CONCLUSION: 
In summary, our results indicate that the giant liposomes prepared from cholesterol and soy 
lecithin (1:12) mixture at 55
0
C temperature by using ether infusion homogenization method 
which can be stable at room temperature and 4
0
C temperature and also in PBS can be used 
for systemic application because liposome bilayer is composed of lipids is compatible to 
blood components. It can be use in drug delivery application by encapsulating the drug 
loaded giant liposomes inside hydrogel because giant liposome have the storage capability 
and hydrogel have the ability to absorb large amount of water and it is biocompatible and 
biodegradable. The cytotoxic index of drug loaded liposomes is very low and by the 
incorporation of liposome the strength of the gel increases. 
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